Live Breaking News & Updates on Vimal mehta

Stay informed with the latest breaking news from Vimal mehta on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Vimal mehta and stay connected to the pulse of your community

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) CEO Sells $13,802.16 in Stock

BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) CEO Vimal Mehta sold 5,268 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $2.62, for a total transaction of $13,802.16. Following the sale, the chief executive officer now owns 43,564 shares of the company’s […]

United-states , Cambridge , Cambridgeshire , United-kingdom , America , Vimal-mehta , Virtu-financial , Barclays-plc , Canaccord-genuity-group , Securities-exchange-commission , Bioxcel-therapeutics-inc , Tower-research-capital

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript March 12, 2024 BioXcel Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.76, expectations were $-0.98. BioXcel Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome […]

Richard-steinhart , Vimal-mehta , Most-advanced-countries-in-international , Xcel-therapeutics , With-the-highest-number , Internet-users , Advanced-countries ,

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Japan , Vimal-mehta , Brennan-doyle , Erik-kopp , David-schull , Scott-stachowiak , Development-rd-expenses , Securities-exchange , While-the-company , Drug-administration , Bioxcel-therapeutics-inc , Aboutbioxceltherapeutics-inc

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Matt-coffey , Thomas-heineman , Abderrahim-oukessou , Dirk-arnold , Vimal-mehta , Neeraj-agarwal , Bristol-myers-squibb , Oncolytics-biotech , Exelixis-inc , Twitter

FDA Grants Fast Track Designation to BXCL701 for Small Cell Neuroendocrine Prostate Cancer

BXCL701 has been granted fast track designation for select patients with metastatic small cell neuroendocrine prostate cancer by the FDA.

Vimal-mehta , Vincentj-oneill , Prostate-cancer-working-group , Product-development , Bioxcel-therapeutics-inc , Bioxcel-therapeutics , Onkosxcel-therapeutics , Cancers-symposium , Medical-officer , Xcel-therapeutics , Bxcl701

Novel Drug Granted FDA Fast Track in Rare Prostate Cancer Subset

The Food and Drug Administration has granted a Fast Track designation to the novel immune activator drug BXCL701 in combination with a checkpoint inhibitor for patients with metastatic small cell neuroendocrine prostate cancer (SCNC).

Vincentj-oneill , Vimal-mehta , Drug-administration , Fast-track , Medical-officer , Bioxcel-therapeutics , Onkosxcel-therapeutics , News , Prostate-cancer , Fda ,

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Relationsbioxcel-therapeuticsbrennan-doyle , Scott-stachowiak , Mediarusso-partnersdavid-schull , Vimal-mehta , Vincentj-oneill , Corporatebioxcel-therapeuticserik-kopp , Bioxcel-therapeutics-inc , Nasdaq , Aboutbioxceltherapeutics-inc , Product-development

AI Stock/Biotech Stock News Bite - BioXcel Therapeutics (NASDAQ:BTAI) Announces USPTO's Allowance of Patent Application

AI Stock/Biotech Stock News Bite - BioXcel Therapeutics (NASDAQ:BTAI) Announces USPTO's Allowance of Patent Application

United-states , Vimal-mehta , Twitter , Youtube , Drug-administration , Bioxcel-therapeutics-inc , Nasdaq , Facebook , Trademark-office , Biotech-stock-news , Bioxcel-therapeutics , United-states-patent

BioXcel Therapeutics Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine -February 05, 2024 at 07:01 am EST

Aligns with Company’s strategic focus on bringing to market BXCL501 for potential acute treatment of agitation for Alzheimer’s patients IGALMI™ market exclusivity further strengthened with...

United-states , Vimal-mehta , Brennan-doyle , David-schull , Erik-kopp , Scott-stachowiak , Nasdaq , Securities-exchange , Globenewswire-inc , While-the-company , Trademark-office , Drug-administration

BioXcel Therapeutics Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine

BioXcel Therapeutics Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United-states , David-schull , Erik-kopp , Vimal-mehta , Scott-stachowiak , Brennan-doyle , Securities-exchange , While-the-company , Bioxcel-therapeutics-inc , Drug-administration , Nasdaq , Trademark-office